Electrochemotherapy Shows Promise in Treating Large and Deep-Seated Soft Tissue Sarcomas
A recent pilot study published in Nature has shed light on the effectiveness of electrochemotherapy (ECT) in treating large and deep-seated soft tissue sarcomas. The study, conducted at Imam-Khomeini Hospital in Tehran, Iran, evaluated the treatment's ability to provide symptom relief, tumor control, and limb preservation in patients with advanced recurrent, metastatic, or locally aggressive soft tissue sarcomas.
The study involved 25 patients who underwent ECT between 2022 and 2025. The treatment combined bleomycin chemotherapy with reversible electroporation to enhance intracellular drug delivery. The results showed that overall symptom palliation was achieved in 88.9% of symptomatic patients, with significant pain reduction reported in 85.7% of patients with severe baseline pain. Additionally, complete cessation of bleeding and tumor-associated discharge was observed in all eight affected patients.
The study also found that quality of life improved across all evaluated domains, including Global Health, Physical Function, and Role Function, while Pain and Other Symptoms scores decreased significantly. The treatment was well tolerated, with no severe treatment-related toxicity reported.
The study's findings suggest that ECT may be a viable treatment option for patients with advanced soft tissue sarcomas, particularly those with large and deep-seated tumors. However, further research is needed to confirm these results and explore the long-term effects of the treatment.
